Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Safety was equally impressive. ENV-294 was well tolerated
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
